Tengion, Inc.

Equities

TNGNQ

US88034G2084

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 14:30:00 23/05/2024 BST			5-day change	1st Jan Change
0.000001 ^USD	0.00%		0.00%	0.00%

2023	Tengion, Inc. Went Out of Business	CI
2022	Bankruptcy Judge Changed for Tengion, Inc.	CI

Tengion, Inc. Promotes A. Brian Davis to Chief Financial Officer and Senior Vice President, Finance

August 07, 2013 at 01:30 pm

Tengion, Inc. announced the promotion of A. Brian Davis to Chief Financial Officer and Senior Vice President, Finance. Prior to joining Tengion, Mr. Davis served 15 years at Neose Technologies, Inc., where he advanced from Controller to Senior Vice President, Finance and CFO.

Latest news about Tengion, Inc.

Tengion, Inc. Went Out of Business	11-20	CI
Bankruptcy Judge Changed for Tengion, Inc.	25/02/22	CI
RegenMedTX, LLC completed the acquisition of substantially all assets from Tengion, Inc. (OTCPK:TNGN.Q).	31/03/15	CI
Motion for Private Asset Sale Approved for Tengion, Inc.	06/03/15	CI
Order Approving Private Sale Agreement for Tengion, Inc.	20/02/15	CI
Motion for Asset Sale Filed by Chapter 7 Trustee for Tengion, Inc.	12/02/15	CI
RegenMedTX, LLC signed an agreement to acquire substantially all assets from Tengion, Inc. (OTCPK:TNGN.Q) for $22.1 million.	12/02/15	CI
Tengion, Inc. will Change its Ticker to TNGNQ from TNGN	31/12/14	CI
Tengion, Inc. Filed for Bankruptcy	29/12/14	CI
Tengion, Inc. Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014	14/11/14	CI
Tengion Considers A Strategic Review	22/09/14	CI
Tengion, Inc. Announces Unaudited Earnings Results for Second Quarter and Six Months Ended June 30, 2014; Provides Clinical Update	13/08/14	CI
Tengion, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2014	15/05/14	CI
Tengion, Inc. Auditor Raises 'Going Concern' Doubt	26/03/14	CI
Tengion, Inc. Announces Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013	26/03/14	CI
Tengion, Inc. Announces Continued Clinical Progress in its Two Lead Programs	13/01/14	CI
Tengion, Inc. Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2013	14/08/13	CI
Tengion, Inc. Promotes A. Brian Davis to Chief Financial Officer and Senior Vice President, Finance	07/08/13	CI
Tengion, Inc. announced that it has received $18.60 million in funding from a group of investors.	28/06/13	CI
Tengion, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2013	15/05/13	CI
Tengion Receives MPA Approval of CTA for Neo-Kidney Augment Phase 1 Trial in Sweden	01/04/13	CI
Tengion, Inc. Auditor Raises 'Going Concern' Doubt	26/03/13	CI
Transcript : Tengion, Inc., Q4 2012 Earnings Call, Mar 18, 2013	18/03/13
Tengion, Inc. Reports Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2012	18/03/13	CI
Tengion, Inc. Announces Clinical Progress for Neo-Urinary Conduit Phase 1 Trial and Regulatory Advance for Neo-Kidney Augment	30/01/13	CI

Chart Tengion, Inc.

Duration

Period

More charts

Company Profile

Tengion, Inc. is a regenerative medicine company focused on discovering, developing, manufacturing and commercializing a range of neo-organs, or products composed of living cells, with or without synthetic or natural materials, implanted or injected into the body to engraft into, regenerate, or replace a damaged tissue or organ. Â The Company, by using its Organ Regeneration Platform, it creates neo-organs using patientâs own cells. Â The Company, based on its clinical and preclinical experience is leveraging its Organ Regeneration Platform to develop Neo-Kidney Augment for patients with advanced chronic kidney disease and Neo-Urinary Conduit for bladder cancer patients who are in need of a urinary diversion. The Companyâs product candidates are intended to delay or eliminate the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Medical Devices

	1st Jan change	Capi.
TENGION, INC.	0.00%	40
MIMEDX GROUP, INC.	-12.26%	1.14B
NIBEC CO., LTD.	-25.17%	122M
COLLPLANT BIOTECHNOLOGIES LTD.	-9.55%	65.98M
KIM FOREST ENTERPRISE CO., LTD.	+1.08%	59.29M
BONUS BIOGROUP LTD.	+1.20%	53.68M

Bio Medical Devices